5-ALA Publications


Notice Regarding Joint Study Using Dietary Supplement Containing 5-Aminolevulinate Phosphate and Sodium Ferrite Citrate in Patients with Coronavirus Infection (COVID-19)

29 March 2021
Photonamic GmbH & Co. KG (Headquarters: Pinneberg, Germany, Representative: Ulrich Kosciessa, Ph.D. , SBI Pharma Co., Ltd. (Headquarters: Minato-ku, Tokyo, ...Read More

5-amino levulinic acid inhibits SARS-CoV-2 infection in vitro

20 January 2021
Author links open overlay panel YasuteruSakuraiab, Mya MyatNgwe Tunc, YoheiKurosakiab, TakayaSakurad, Daniel KenInaokadf, KiyotakaFujinee, KiyoshiKitafg, KouichiMoritac, JiroYasudaab Department of Emerging ...Read More

Safety, Tolerability, and Efficacy of 5-Aminolevulinic Acid Phosphate, an Inducer of Heme Oxygenase 1, in Combination with Sodium Ferrous Citrate for the Treatment of COVID-19 Patients

13 January 2021
Kazutoshi Kaketani, M.D., Ph.D.1 * and Motowo Nakajima, Ph.D. 2 1Hanzomon Gastrointestinal Clinic, Tokyo 102-0083, and 2 SBI Pharmaceuticals Co. ...Read More

Protoporphyrin IX and verteporfin potently inhibit SARS-CoV-2 infection in vitro and in a mouse model expressing human ACE2

1 December 2020
Author links open overlay panel ChenjianGua1, YangWua1HuiminGuoa1, YuanfeiZhua1, WeiXua, YuyanWanga, YuZhouc, ZhipingSunb, XiaCaib, YutangLia, JingLiua, ZhongHuangc, ZhenghongYuana, RongZhanga, QiangDenga, DiQuab, ...Read More

Heme oxygenase-1 modulation: A potential therapeutic target for COVID-19 and associated complications

19 October 2020
Author links open overlay panel Devendra Singh Himika Wasan K.H.Reeta Department of Pharmacology, All India Institute of Medical Sciences, New ...Read More

Safety and Mode of Action of Diabetes Medications in comparison with 5-Aminolevulinic Acid (5-ALA)

6 November 2019
Peter R. Rehani,1 Hanaa Iftikhar,2 Motowo Nakajima,3 Tohru Tanaka,3 Zaid Jabbar,4 and Riyadh N. Rehani5 Conclusion: The provided analysis of the different mechanisms of action of ...Read More

Announced the results of joint research on the development of a treatment for mitochondrial disease using 5-aminolevulinic acid and sodium ferrous citrate

9 August 2019
SBI Pharma Co., Ltd. Saitama Medical University Chiba Children’s Hospital Juntendo University SBI Pharma Co., Ltd. (Location: Minato-ku, Tokyo, President: ...Read More

Oral administration of 5-aminolevulinic acid induces heme oxygenase-1 expression in peripheral blood mononuclear cells of healthy human subjects in combination with ferrous iron

10 May 2018
Author links open overlay panel HidenoriItoa1, YoshiakiNishiob1, TakeshiHaraa, HidemitsuSugiharaa, TohruTanakaa, Xiao-KangLib SBI Pharmaceuticals Co., Ltd., 1-6-1 Roppongi, Minato-ku, Tokyo 106-6020 ...Read More

The Relationship of 5-Aminolevulinic Acid on Mood and Coping Ability in Prediabetic Middle Aged and Older Adults

4 April 2018
by Rachael K. Aquino 1,*, Michael Perez 1, Payel Sil 2, Terry Shintani1, Rosanne Harrigan 1,† and Beatriz Rodriguez1,3,*   Department of Geriatrics and Department of ...Read More

Notice of Receipt of the Minister of Economy, Trade and Industry Award, Japan Bio-Venture Awards

18 January 2017
Notice of Receipt of the Minister of Economy, Trade and Industry Award, Japan Bio-Venture Awards SBI Pharma Co., Ltd.   ...Read More

News Page – Disclaimer

The purpose of this page is to provide you an overview of the business in the industry & market information. Information in this page are derived from internal estimates, studies, researches conducted by third parties and general publications, as well as from sources that are considered reliable, by ABBACI Health (hereinafter referred to as “producers”). Industry publications, studies, and surveys usually indicate the data used are originated from sources that are considered reliable, but no guarantee upon the accuracy or completeness of such data. Producers believe these studies and publications are safe, but they have not independently verified the market and industry data from third-party sources. Similarly, producers think that their internal researches and information about the company is reliable, but not independently validated. Therefore, the content of this prospectus and its accuracy, including the realization or reasonableness of any forecasts, management estimates, prospects or returns, are not expressed or guaranteed by the producers.

The producer is not responsible for providing updates, corrections or other new data for any of the prospectus. This page contains forecasts, as well as potential future events, possible outcomes and projected growth (collectively referred to as “forward-looking statements” or “forward-looking projections”). Producers and their employees are not responsible for relying on or using the data of
this page, or/and any liability of any nature to further convey the relevant data in writing or verbally. As this page is a confidential document, the content is strictly regulated and, without the express consent of the company or the producer, all or part of the data of this page may not be used, reproduced, transmitted, altered, published, stored, duplicated or otherwise used for any purpose.

This document is for informational purposes only and does not constitute an offer, advertisement or invitation to the public.